Homozygous deletion but not mutation of exons 5 and 8 of the Fragile Histidine Triad (FHIT) gene is associated with features of differentiated thyroid carcinoma

Annals of Clinical and Laboratory Science

Volumn 40, Issue 3, 2010, Pages 267-272

  Yin, De Tao ^a,b   Wang, Lin ^a   Sun, Jianrei ^a   Yin, Fengyan ^a   Yan, Qingtao ^b   Shen, Ru Long ^b   Gao, Jian Xin ^b   He, Gang ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Differentiated thyroid carcinoma; Fragile histidine triad; Homozygous deletion

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATIONAL STUDY; EXON; FEMALE; GENE DELETION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; CHROMOSOME FRAGILE SITES; CHROMOSOMES, HUMAN, PAIR 3; EXONS; FEMALE; HOMOZYGOTE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SEQUENCE DELETION; THYROID GLAND; THYROID NEOPLASMS; YOUNG ADULT;

EID: 77955826140     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Shaha A. TNM classification of thyroid carcinoma. World J Surg 2007;31:879-887.
2. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008;46:1067-1073.
3. Ishii H, Mimori K, Ishikawa K, Okumura H, Pichiorri F, Druck T, Inoue H, Vecchione A, Saito T, Mori M, Huebner K. FHIT-deficient hematopoietic stem cells survive hydroquinone exposure carrying precancerous changes. Cancer Res 2008;68:3662-3670.
4. Cao J, Li W, Xie J, Du H, Tang W, Wang H, Chen X, Xiao W, Li Y. Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg Oncol 2006;15:223-233.
5. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA, Huebner K. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 2006;232:27-36.
6. Holschneider CH, Baldwin RL, Tumber K, Aoyama C, Karlan BY. The fragile histidine triad gene: A molecular link between cigarette smoking and cervical cancer. Clin Cancer Res 2005;11:5756-5763.
7. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-597.
8. Huebner K, Hadaczek P, Siprashvili Z, Druck T, Croce CM. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, fra3b. Biochim Biophys Acta 1997;1332: M65-M70.
9. Moulin AP, Clement G, Bosman FT, Zografos L, Benhattar J. Methylation of cpg island promoters in uveal melanoma. Br J Ophthalmol 2008, 92:281-285.
10. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R. Promoter hypermethylation of p16ink4a, e-cadherin, o6-mgmt, dapk and fhit in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol 2005;26: 1493-1500.
11. Lee EJ, Lee BB, Kim JW, Shim YM, Hoseok I, Han J, Cho EY, Park J, Kim DH. Aberrant methylation of fragile histidine triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 2006;42:972-980.
12. Kuroki T, Tajima Y, Furui J, Kanematsu T. Common fragile genes and digestive tract cancers. Surg Today 2006;36:1-5.
13. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FHIT/fra3b locus in cancer. Ann Rev Genetics 2003;32:7-31.
14. Kisselev LL, Justesen J, Wolfson AD, Frolova LY. Diadenosine oligophosphates (apna), a novel class of signalling molecules? FEBS Lett 1998;427:157-163.
15. McIver B, Grebe SK, Wang L, Hay ID, Yokomizo A, Liu W, Goellner JR, Grant CS, Smith DI, Eberhardt NL. FHIT and tsg101 in thyroid tumours: Aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin Endocrinol 2000;52:749-757.
16. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R, Huebner K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005;24:1625-1633.
17. LiVolsi VA A-SJ, Asa SL, Baloch ZW, Sobrinho-Simoes M, Wenig B, DeLellis RA, Cady B. Papillary carcinoma (World Health Organization Classification of Tumors). In: Pathology and Genetics of Tumours of Endocrine Organs (De Lellis RA LR, Heitz PU, Eng C, Eds), IARC Press, Lyon, 2004; pp 57-66.
18. Hermanek P, Sobin LH. Tnm Classification of Malignant Tumors. Springer Verlag, Berlin, 1987.
19. Sambrook JF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Lab Press, Cold Spring Harbor, NY, 1989.
20. Uzawa N, Akanuma D, Negishi A, Iwaki H, Uzawa Y, Amagasa T, Yoshida MA. Homozygous deletions on the short arm of chromosome 3 in human oral squamous cell carcinomas. Oral Oncol 2001;37:351-356.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific pcr: A novel PCR assay for methylation status of cpg islands. PNAS USA 1996;93: 9821-9826.
22. Kajiwara H, Kaneko T. Utility of single-strand conformation polymorphism analysis was improved by low-cross- linking polyacrylamide gel and quick low-background silver staining. Anal Biochem 2002;300:273-274.
23. Powell DJ Jr., Russell JP, Li G, Kuo BA, Fidanza V, Huebner K, Rothstein JL. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from ret/ptc3p53-/- mice. Oncogene 2001;20:3235-3246.
24. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk YM, Rynditch AV, Vozianov AF. Hypermethylation of the 5'cpg island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 2008;265:250-257.
25. Wu Y, Meng L, Wang H, Xu Q, Wang S, Wu S, Xi L, Zhao Y, Zhou J, Xu G, Lu Y, Ma D. Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis. Oncol Rep 2006;16:625-629.
26. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol 2007;17:31-41.
27. Smith DI, Zhu Y, McAvoy S, Kuhn R. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 2006;232:48-57.
28. Mandai M, Konishi I, Kuroda H, Nanbu K, Matsushita K, Yura Y, Hamid AA, Mori T. Expression of abnormal transcripts of the FHIT (fragile histidine triad) gene in ovarian carcinoma. Eur J Cancer 1998;34:745-749.
29. Shabtai F, Klar D, Hart J, Halbrecht I. On the meaning of fragile sites in cancer risk and development. Cancer Genet Cytogenet 1985;18:81-85.
30. Güven G, Hacihanefioǧlu S, Cenani A. Expression of aphidicolin, fudr and caffeine-induced fragile sites in lymphocytes of healthy Turkish individuals. Genetica 1999;105:109-116.
31. Sutherland GR, Baker E, Richards RI. Fragile sites still breaking. Trends Genet 1998;14:501-506.
32. Tunca B, Cecener G, Gebitekin C, Egeli U, Ediz B, Ercan I. Investigation of genetic susceptibility to non-small cell lung cancer by fragile site expression. Teratog Carcinog Mutagen 2002;22:205-215.
33. Ko JY, Lee TC, Hsiao CF, Lin GL, Yen SH, Chen KY, Hsiung CA, Chen PJ, Hsu MM, Jou YS. Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT, p16(ink4a), and p19(arf) genes in nasopharyngeal carcinoma. Cancer 2002;94:1987-1996.
34. Kannan K, Krishnamurthy J, Feng J, Nakajima T, Tsuchida N, Shanmugam G. Mutation profile of the p53, FHIT, p16ink4a/p19arf and h-RAS genes in Indian breast carcinomas. Int J Oncol 2000;17:1031-1035.
35. Zou M, Shi Y, Farid NR, Al-Sedairy ST, Paterson MC. FHIT gene abnormalities in both benign and malignant thyroid tumours. Eur J Cancer 1999;35:467-472.
36. Kannan K, Munirajan AK, Bhuvarahamurthy V, Mohanprasad BKC, Shankar P, Tsuchida N, Shanmugam G. FHIT gene mutations and single nucleotide polymorphism in Indian oral and cervical squamous cell carcinomas. Oral Oncol 2000;36:189-193.
37. Knudson AG. Anti-oncogenes and human cancer. PNAS USA 1993;90:10914-10921.
38. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: From gene discovery to cancer treatment and prevention. Lancet Oncol 2002;3:748-754.
39. Foja S, Goldberg M, Schagdarsurengin U, Dammann R, Tannapfel A, Ballhausen WG. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas. Liver Internat 2005;25:1202-1208.
40. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T. Promoter hypermethylation of RAS-sf1a and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007;58:131-138.
41. Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin HD, Luo M, Su HX, Zhou SB, Xie KQ. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res 2009, 37:927-938.